Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Bupropion/naltrexone> ?p ?o. }
Showing items 1 to 38 of
38
with 100 items per page.
- naltrexone abstract "Bupropion/naltrexone (proposed trade name Contrave) is an experimental treatment for obesity in phase III clinical trials. Currently being developed by Orexigen in a sustained-release formulation, it is a combination of two approved drugs, bupropion and naltrexone. Both drugs have individually shown some evidence of effectiveness in weight loss, and the combination is expected to have a synergistic effect. In clinical trials, patients taking Contrave combined with diet and exercise lost more weight than patients taking a placebo and following the same diet and exercise program. On 31 March 2010, Orexigen submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for this drug combination. On 7 December 2010, an FDA Advisory Committee voted 13-7 for the approval of Contrave, and voted 11-8 for the conduct of a post-marketing cardiovascular outcomes study. Contrave's PDUFA date was 31 January 2011. Subsequently, on 2 February 2011, the FDA rejected the drug and it was decided that an extremely large-scale study of the long-term cardiovascular effects of Contrave would be needed, before approval could be considered. The recommended daily dose of Contrave is two (8 mg naltrexone/90 mg bupropion) tablets taken twice daily (4 tablets total - 32 mg naltrexone, 360 mg bupropion). Upon initiation, the drug will be started with a quarter-dose (or one tablet) for one week and a pill will be added to the regimen each week until the full recommended dose is reached on Week 4. During phase 2 testing, different dosages were used in a once daily formula. These include: 16 mg naltrexone - 400 mg bupropion 32 mg naltrexone - 400 mg bupropion 48 mg naltrexone - 400 mg bupropionThe second dosage (32 mg-400 mg) on average showed the best benefit-to-risk ratio.Treatment is designed to influence the hypothalamus in order to decrease food intake over an extended period of time. Studies of almost 700 patients, 90% female, ran up to 56 weeks. The control group, overall, lost 5% of their initial body weight, or 11-16 lbs. The experimental (medicated) group lost 20-23 lbs during the same amount of time. The average starting weight for participants was 223 lbs. Current medical weight loss medications average 5-22 lbs lost in 6 months.".
- naltrexone wikiPageID "22496469".
- naltrexone wikiPageRevisionID "563025043".
- naltrexone class Dopamine_reuptake_inhibitor.
- naltrexone class Norepinephrine_reuptake_inhibitor.
- naltrexone class Opioid_receptor.
- naltrexone class Receptor_antagonist.
- naltrexone component "Bupropion".
- naltrexone component "Naltrexone".
- naltrexone hasPhotoCollection naltrexone.
- naltrexone type "combo".
- naltrexone verifiedrevid "432618382".
- naltrexone subject Category:Anorectics.
- naltrexone subject Category:Antiobesity_drugs.
- naltrexone subject Category:Combination_drugs.
- naltrexone type Anorectics.
- naltrexone type Anorexic109795751.
- naltrexone type CausalAgent100007347.
- naltrexone type LivingThing100004258.
- naltrexone type Object100002684.
- naltrexone type Organism100004475.
- naltrexone type Person100007846.
- naltrexone type PhysicalEntity100001930.
- naltrexone type SickPerson110595647.
- naltrexone type Unfortunate109630641.
- naltrexone type Whole100003553.
- naltrexone type YagoLegalActor.
- naltrexone type YagoLegalActorGeo.
- naltrexone type Drug.
- naltrexone type FunctionalSubstance.
- naltrexone comment "Bupropion/naltrexone (proposed trade name Contrave) is an experimental treatment for obesity in phase III clinical trials. Currently being developed by Orexigen in a sustained-release formulation, it is a combination of two approved drugs, bupropion and naltrexone. Both drugs have individually shown some evidence of effectiveness in weight loss, and the combination is expected to have a synergistic effect.".
- naltrexone label "Bupropion/naltrexone".
- naltrexone sameAs m.05zl421.
- naltrexone sameAs Q4998036.
- naltrexone sameAs Q4998036.
- naltrexone sameAs naltrexone.
- naltrexone wasDerivedFrom naltrexone?oldid=563025043.
- naltrexone isPrimaryTopicOf naltrexone.